Trials / Completed
CompletedNCT07531069
Efficacy and Safety of Interferon-Gamma Monoclonal Antibody Combined With Dexamethasone in the Treatment of Refractory Adult Secondary Hemophagocytic Lymphohistiocytosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 22 (actual)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to learn if interferon-gamma monoclonal antibody combined with dexamethasone works to treat adults with refractory secondary hemophagocytic lymphohistiocytosis (HLH). The main questions it aims to answer are: How well does this treatment help patients recover from refractory secondary HLH? How safe is this treatment for these patients? Participants will receive interferon-gamma monoclonal antibody and dexamethasone as part of their clinical care. Researchers will monitor participants with regular blood tests, physical exams, and safety checks for up to 8 weeks of treatment. They will collect information about how participants respond to treatment and any side effects that occur. This study will include about 22 adult participants at Huadong Hospital Affiliated to Fudan University.
Conditions
- Adult Refractory Secondary Hemophagocytic Lymphohistiocytosis
- Secondary Hemophagocytic Lymphohistiocytosis
- HLH
Timeline
- Start date
- 2024-05-21
- Primary completion
- 2025-08-31
- Completion
- 2025-08-31
- First posted
- 2026-04-15
- Last updated
- 2026-04-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07531069. Inclusion in this directory is not an endorsement.